Bladder Cancer, An Issue of Hematology/Oncology Clinics of North America

1st Edition, Volume 35-3 - May 14, 2021
Editor: Guru P. Sonpavde
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 7 6 4 5 1 - 3
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 7 6 4 5 2 - 0

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. Guru P. Sonpavde, is devoted to Bladder Cancer. This issue is one of six selected each year by our series Consulting… Read more

Bladder Cancer, An Issue of Hematology/Oncology Clinics of North America

Purchase options

Info / Buy

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. Guru P. Sonpavde, is devoted to Bladder Cancer. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Epidemiology of bladder cancer, The molecular biology of bladder cancer and potential implications for therapy, Current therapy for metastatic urothelial carcinoma, Current perioperative therapy for muscle invasive urothelial carcinoma, Current therapy and emerging intravesical agents to treat non-muscle invasive bladder cancer, Diagnosis and staging of bladder and upper tract urothelial cancer, Surgery for bladder and upper tract urothelial cancer, Bladder conserving therapy for muscle invasive bladder cancer: opportunities to incorporate molecular profiling, Emerging immunotherapy for bladder cancer, Emerging targeted therapy for bladder cancer, Real world outcomes of patients with bladder cancer, Preclinical systems to develop bladder cancer therapeutics, Developing precision medicine for bladder cancer, and Future Directions in Bladder Cancer Treatment and Research.

Cover image
Title page
Table of Contents
Copyright
Contributors
Forthcoming Issues
Preface
The Epidemiology of Bladder Cancer
Key points
Background
Survival
Risk factors
Summary and clinics care points
Molecular Biology of Bladder Cancer: Potential Implications for Therapy
Key points
Introduction and history
Molecular heterogeneity of bladder cancer: molecular subtypes
Molecular heterogeneity of bladder cancer: stromal cells
DNA mutations in carcinogenesis and response to therapy
Ongoing studies and future directions
Clinics care points
Current Therapy for Metastatic Urothelial Carcinoma
Key points
Systemic chemotherapy in advanced urothelial cancer
Immune checkpoint inhibitors in advanced urothelial carcinoma
Targeting fibroblast growth receptor in advanced urothelial carcinoma
Antibody-drug conjugates in advanced urothelial cancer
Antiangiogenic therapy in urothelial carcinoma
Targeting endothelial growth factor receptor family in advanced urothelial carcinoma
Other targeted therapies in advanced urothelial carcinoma
Summary
Conflict of interest statement
Clinics care points
Current Perioperative Therapy for Muscle Invasive Bladder Cancer
Key points
Introduction
Perioperative radiotherapy
Perioperative chemotherapy
Perioperative immunotherapy
Summary
Clinics care points
Current Therapy and Emerging Intravesical Agents to Treat Non–Muscle Invasive Bladder Cancer
Key points
Introduction
Risk-adopted intravesical therapy (bacillus Calmette-Guérin naive)
Intravesical therapies for non–muscle invasive bladder cancer following bacillus Calmette-Guérin failure
Summary
Clinics care points
Diagnosis and Staging of Bladder Cancer
Key points
Introduction
Discussion
Summary
Clinics care points
Surgery for Bladder and Upper Tract Urothelial Cancer
Key points
Introduction
Surgery for bladder cancer
Surgery for upper tract urothelial cancer
Summary
Clinics care points
Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer
Key points
Bladder-preserving trimodality therapy: a modern standard of care for muscle-invasive bladder cancer
Opportunities to incorporate molecular profiling
Summary
Clinics care points
Emerging Targeted Therapy for Bladder Cancer
Key points
Introduction
Fibroblast growth factor receptor inhibitors
PARP inhibitors
Antibody-drug conjugates
Antiangiogenic therapies
Other promising targeted therapies
Discussion
Clinics care points
Disclosure
Real World Outcomes of Patients with Bladder Cancer: Effectiveness Versus Efficacy of Modern Treatment Paradigms
Key points
Introduction
Non–muscle invasive bladder cancer
Muscle invasive bladder cancer
Advanced bladder cancer
Summary
Clinics care points
Preclinical Models for Bladder Cancer Research
Key points
In vitro two-dimensional models
In vitro three-dimensional models
In vivo models
Patient-derived xenograft models
Humanized models
Summary
Disclosure
Developing Precision Medicine for Bladder Cancer
Key points
Introduction
Discussion
Summary
Clinics care points
Disclosure
Future Directions in Bladder Cancer Treatment and Research—The Patient Advocates’ Perspective
Key points
Introduction
Discussion
Summary